Emergent BioSolutions Reports Third-Quarter 2026 Financial Results
Emergent BioSolutions reported third-quarter results for the period ended September 30, 2026, including revenue of $110.0 million, in line with its guidance.
Story updates
09:06:45 PM UTC
SquawkNews
Emergent Biosolutions 3Q Loss/Shr 64c >EBS
09:06:48 PM UTC
SquawkNews
Emergent Biosolutions 3Q Loss $32.7M >EBS
09:06:55 PM UTC
SquawkNews
Emergent BioSolutions reported unaudited Q3 2026 revenue of $110.0M, in line with guidance. Compared with Q3 2025, revenue fell across several product categories, including Smallpox MCM, down $56.9M or 68%.Material DetailsContext by AI AnalystThis is a quarterly update during the company's stated t…
09:08:23 PM UTC
SquawkNews
Nov 02 (Reuters) - Emergent BioSolutions Q3 gross margin 14%.
Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the third quarter ended September 30, 2026.“Emergent's third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medical countermeasures and nalo…